Abbott Laboratories (ABT) is Reiterated by RBC Capital Mkts to Outperform, Raises Price Target to $ 48

Abbott Laboratories (ABT) was Reiterated by RBC Capital Mkts to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 48 from a previous price target of $45 . RBC Capital Mkts advised their investors in a research report released on Apr 11, 2016.

Many Wall Street Analysts have commented on Abbott Laboratories. Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 45 from a previous price target of $51 .

On the company’s financial health, Abbott Laboratories reported $0.62 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $0.61. The company had revenue of $5188.00 million for the quarter, compared to analysts expectations of $5254.57 million. The company’s revenue was down -3.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.71 EPS.

Abbott Laboratories opened for trading at $42.47 and hit $42.88 on the upside on Monday, eventually ending the session at $42.48, with a gain of 0.26% or 0.11 points. The heightened volatility saw the trading volume jump to 39,48,803 shares. Company has a market cap of $62,583 M.

Investors should note that on Feb 19, 2016, Abbott Laboratories announced a cash dividend of $0.2600. The company’s management has announced Apr 13, 2016 as the ex-dividend date and fixed the record date on Apr 15, 2016. The payable date has been fixed on May 16, 2016.

In a different news, on Mar 2, 2016, Robert B Ford (Executive Vice President) sold 1,706 shares at $39.28 per share price. According to the SEC, on Mar 2, 2016, Deepak S. Nath (Senior Vice President) sold 793 shares at $39.27 per share price. On Mar 2, 2016, Stephen R Fussell (Executive Vice President) sold 1,402 shares at $39.26 per share price, according to the Form-4 filing with the securities and exchange commission.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Abbott Laboratories

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.